Guideline Recommendations for Migraine Prevention

First‑Line Preventive Options

CGRP‑Targeted Therapies (Preferred)

Traditional First‑Line Agents (Cost‑Effective Alternatives)

Second‑Line Options (When First‑Line Fails or Is Contraindicated)

Chronic Migraine‑Specific Treatment

Agents to Avoid or Use Cautiously

Indications to Initiate Preventive Therapy

Implementation and Access Considerations

Adjunctive Approaches

Metoprolol for Migraine Prophylaxis

Efficacy and Evidence

• Metoprolol is an established first‑line medication for migraine prophylaxis, with strong evidence supporting its effectiveness in reducing migraine frequency and severity. 3

Guideline Recommendations

• The 2023 VA/DoD Headache Guidelines, the 2025 American College of Physicians Guidelines, and the 2012 American Academy of Neurology/American Headache Society Guidelines all give metoprolol a strong recommendation as a first‑line preventive agent for episodic migraine. 3

Comparative Effectiveness

• Comparative studies indicate that metoprolol is as effective as propranolol for migraine prophylaxis, confirming its status as a viable beta‑blocker option in this indication. 3

Initiating Preventive Medication for Migraine

Indications for Starting Preventive Therapy

• Patients experiencing four or more migraine days per month should be offered preventive medication, regardless of acute treatment adequacy. 4
• Patients with two or more migraine days per month accompanied by significant disability despite appropriate acute therapy merit preventive treatment. 4
• Severe, debilitating headaches that markedly impair quality of life despite use of adequately‑strengthened acute medications are an indication for prevention. [5][6]
• Frequent acute medication use (≥ 7 days/month) or the presence of medication‑overuse headache risk justifies initiation of preventive therapy. 4
• Contraindications or intolerance to acute migraine treatments constitute a reason to start preventive medication. [5][6]
• When patients prefer preventive therapy over repeated acute medication use, clinicians should honor that preference. 5

Frequency Thresholds and Guideline Recommendations

• The 2024 VA/DoD guidelines recommend initiating preventive therapy at ≥ 4 migraine days/month, or at ≥ 2 days/month when significant disability is present. This threshold is lower than older recommendations and is based on evidence that earlier intervention reduces progression to chronic migraine. 4
• No universally rigid, evidence‑based thresholds exist; clinicians must apply clinical judgment regarding disability and quality‑of‑life impact. 5

Pre‑Treatment Assessment and Modifiable Factors

• Identify and manage environmental, dietary, and behavioral triggers before starting preventive medication. 5
• Ensure patients maintain adequate hydration, regular sleep patterns, and regular physical activity as part of comprehensive care. 5
• Verify that patients are using appropriate‑strength acute medications and taking them early in attacks. 5
• Screen for medication‑overuse headache when acute analgesics are used ≥ 7 days per month. 4

Clinical Pitfalls to Avoid

• Do not postpone preventive therapy in patients with high disability scores or frequent emergency‑department visits, as these indicate insufficient migraine control. [5][6]
• Counsel patients that clinical improvement typically unfolds gradually over the first few weeks of preventive treatment and that adherence is essential for success. 5

Chronic Migraine Management

• For patients meeting criteria for chronic migraine (≥ 15 headache days per month), preventive therapy is considered standard of care. 4